(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~May 5,~~July 28, 2022, the registrant had ~~28,148,125~~29,248,553 shares of common stock, $0.001 par value per share, outstanding.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Quarterly Report, including without limitation statements regarding our plans to develop, manufacture and commercialize our product candidates, the timing or outcome of our ongoing or planned clinical trials for SQZ-PBMC-HPV, SQZ-AAC-HPV, SQZ-eAPC-HPV or any of our other pipeline product candidates and any future product candidates, the clinical utility of our product candidates, the anticipated impact of the COVID-19 pandemic on our business and operations, including manufacturing, research and development, clinical trials and employees, our cash needs and availability, and the plans and objectives of management for future operations, are forward-looking statements.

The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those projected in the forward-looking statements, including, but not limited to, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors and strategic collaborators; protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets; and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and other filings with the U.S. Securities and Exchange Commission.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.


	MARCH 31,			DECEMBER 31,			JUNE 30,			DECEMBER 31,
	2022			2021			2022			2021
Assets
Current assets:
Cash and cash equivalents	$	122,914		$	143,513		$	105,561		$	143,513
Accounts receivable		—			3,000			—			3,000
Prepaid expenses and other current assets		5,003			4,122			4,491			4,122
Total current assets		127,917			150,635			110,052			150,635
Property and equipment, net		2,885			3,046			2,683			3,046
Restricted cash		2,305			2,305			2,305			2,305
Deferred offering costs		323			323			310			323
Operating lease right-of-use assets		67,367			69,843			64,961			69,843
Total assets	$	200,797		$	226,152		$	180,311		$	226,152
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,204		$	3,971		$	1,656		$	3,971
Accrued expenses		8,526			6,810			9,711			6,810
Current portion of deferred revenue		9,638			12,507			6,630			12,507
Current portion of operating lease liabilities		10,131			9,936			10,446			9,936
Total current liabilities		29,499			33,224			28,443			33,224
Deferred revenue, net of current portion		9,196			9,196			9,196			9,196
Operating lease liabilities, net of current portion		57,188			59,756			54,484			59,756
Total liabilities		95,883			102,176			92,123			102,176
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2022 and December 31, 2021; NaN shares issued or outstanding.		—			—
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2022 and December 31, 2021; 28,148,125 and 28,133,368 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.		28			28
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2022 and December 31, 2021; NaN shares issued or outstanding.								—			—
Common stock, $0.001 par value; 200,000,000 shares authorized at June 30, 2022 and December 31, 2021; 29,148,053 and 28,133,368 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively.								29			28
Additional paid-in capital		321,434			319,458			326,943			319,458
Accumulated deficit		(216,548	)		(195,510	)		(238,784	)		(195,510	)
Total stockholders’ equity		104,914			123,976			88,188			123,976
Total liabilities and stockholders’ equity	$	200,797		$	226,152		$	180,311		$	226,152

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


	THREE MONTHS ENDED MARCH 31,						THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2022			2021			2022			2021			2022			2021
Revenue:
Collaboration revenue	$	2,869		$	5,454		$	3,008		$	4,539		$	5,877		$	9,993
Grant revenue								207			—			207			—
Total revenue								3,215			4,539			6,084			9,993
Operating expenses:
Research and development		17,010			14,740			18,760			17,682			35,771			32,422
General and administrative		6,912			6,120			6,958			5,933			13,870			12,054
Total operating expenses		23,922			20,860			25,718			23,615			49,641			44,476
Loss from operations		(21,053	)		(15,406	)		(22,503	)		(19,076	)		(43,557	)		(34,483	)
Other income (expense):
Interest income	15				9		156				11			172			20
Other income (expense), net		—			(2	)		111			(5	)		111			(6	)
Total other income, net		15			7			267			6			283			14
Net loss and comprehensive loss		(21,038	)		(15,399	)		(22,236	)		(19,070	)		(43,274	)		(34,469	)
Net loss per share, basic and diluted	$	(0.75	)	$	(0.59	)	$	(0.78	)	$	(0.68	)	$	(1.53	)	$	(1.27	)
Weighted-average common shares outstanding, basic and diluted		28,145,036			26,264,019			28,367,355			27,919,647			28,256,810			27,100,817

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


	COMMON STOCK												COMMON STOCK
	SHARES		AMOUNT		ADDITIONAL PAID-IN CAPITAL		ACCUMULATED DEFICIT			TOTAL STOCKHOLDERS’ EQUITY			SHARES		AMOUNT		ADDITIONAL PAID-IN CAPITAL		ACCUMULATED DEFICIT			TOTAL STOCKHOLDERS’ EQUITY
Balances at December 31, 2021		28,133,368	$	28	$	319,458	$	(195,510	)	$	123,976
Issuance of common stock upon exercise of stock options		14,757		—		29		—			29
Balances at March 31, 2022														28,148,125	$	28	$	321,434	$	(216,548	)	$	104,914
Issuance of common stock under employee stock purchase plan														41,265		—		111					111
Issuance of common stock under at-the-market offering, net of issuance costs of $192														958,663		1		3,091					3,092
Stock-based compensation expense		—		—		1,947		—			1,947			—		—		2,307		—			2,307
Net loss		—		—		—		(21,038	)		(21,038	)		—		—		—		(22,236	)		(22,236	)
Balances at March 31, 2022		28,148,125	$	28	$	321,434	$	(216,548	)	$	104,914
Balances at June 30, 2022														29,148,053	$	29	$	326,943	$	(238,784	)	$	88,188


	COMMON STOCK				ADDITIONAL					TOTAL			COMMON STOCK				ADDITIONAL					TOTAL
	SHARES		AMOUNT		PAID-IN CAPITAL		ACCUMULATED DEFICIT			STOCKHOLDERS’ EQUITY			SHARES		AMOUNT		PAID-IN CAPITAL		ACCUMULATED DEFICIT			STOCKHOLDERS’ EQUITY
Balances at December 31, 2020		24,786,324	$	25	$	253,943	$	(126,769	)	$	127,199
Issuance of common stock upon public offering, net of issuance costs of $798		3,000,000		3		55,602		—			55,605
Balances at March 31, 2021														27,881,111	$	28	$	311,425	$	(142,168	)	$	169,285
Issuance of common stock upon exercise of stock options		94,787		—		299		—			299			150,293		—		660		—			660
Stock-based compensation expense		—		—		1,581		—			1,581			—		—		1,829		—			1,829
Net loss		—		—		—		(15,399	)		(15,399	)		—		—		—		(19,070	)		(19,070	)
Balances at March 31, 2021		27,881,111	$	28	$	311,425	$	(142,168	)	$	169,285
Balances at June 30, 2021														28,031,404	$	28	$	313,914	$	(161,238	)	$	152,704

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


	THREE MONTHS ENDED MARCH 31,						SIX MONTHS ENDED JUNE 30,
	2022			2021			2022			2021
Cash flows from operating activities:
Net loss	$	(21,038	)	$	(15,399	)	$	(43,274	)	$	(34,469	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization expense		276			327			558			640
Amortization of operating lease right-of-use assets		2,476			2,474			4,882			4,895
Stock-based compensation expense		1,947			1,581			4,254			3,412
Loss on disposal of equipment		41			—			42			6
Changes in operating assets and liabilities:
Accounts receivable		3,000			1,892			3,000			1,892
Prepaid expenses and other current assets		(881	)		(1,603	)		(369	)		386
Accounts payable		(2,729	)		572			(2,278	)		(793	)
Accrued expenses		1,716			(2,645	)		2,901			(1,818	)
Deferred revenue		(2,869	)		(5,454	)		(5,877	)		(9,767	)
Deferred financing costs								13			—
Operating lease liabilities		(2,373	)		(2,329	)		(4,762	)		(4,609	)
Net cash used in operating activities		(20,434	)		(20,584	)		(40,910	)		(40,225	)
Cash flows from investing activities:
Purchases of property and equipment		(228	)		(247	)		(308	)		(521	)
Proceeds from disposals of property and equipment		34			—			34			—
Net cash used in investing activities		(194	)		(247	)		(274	)		(521	)
Cash flows from financing activities:
Proceeds from follow-on public offering of common stock, net of commissions and underwriting discounts		—			56,400			—			56,400
Payment of public offering costs		—			(1,296	)		—			(1,904	)
Proceeds from issuance of common stock under at-the market offering								3,092			—
Proceeds from issuance of common stock under employee stock purchase plan								111			—
Proceeds from exercise of stock options		29			299			29			960
Net cash provided by financing activities		29			55,403			3,232			55,456
Net (decrease) increase in cash, cash equivalents and restricted cash		(20,599	)		34,572			(37,952	)		14,710
Cash, cash equivalents and restricted cash at beginning of period		145,818			172,662			145,818			172,662
Cash, cash equivalents and restricted cash at end of period	$	125,219		$	207,234		$	107,866		$	187,372
Supplemental disclosure of non-cash investing and financing activities:
Deferred offering costs included in accrued expenses at end of period	$	—		$	605		$	106		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1. Nature of the Business and Basis of Presentation

SQZ Biotechnologies Company (the “Company”) is a clinical-stage biotechnology company developing cell therapies for patients with cancer, autoimmune and infectious diseases and other serious conditions. The Company uses its proprietary Cell Squeeze technology to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. The Company is using Cell Squeeze technology to create multiple cell therapy platforms focused on directing specific immune responses. The Company was incorporated in March 2013 under the laws of the State of Delaware.

The Company is subject to a number of risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, the ability to obtain additional financing, protection of proprietary technology, dependence on key personnel, the ability to attract and retain qualified employees, compliance with government regulations, the impact of the COVID-19 pandemic, and the clinical and commercial success of its product candidates. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with payments received in connection with collaboration agreements, proceeds from equity and debt financing, and most recently, with proceeds from its 2020 initial public offering (“IPO”) and its 2021 follow-on offering. On November 10, 2021, the Company entered into an Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to issue and sell up to $75,000,000 in shares of the Company’s common stock from time to time during the term of the Sales Agreement through an “at-the-market” equity offering program under which Jefferies acts as the Company’s sales agent (the “ATM Facility”). During the three and six months ended June 30, 2022, the Company sold 958,663 shares of common stock under the ATM Facility for net proceeds of approximately $3.1 million. The Company has incurred recurring losses since inception, including net losses of $~~21.0~~43.3 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022. As of ~~March 31,~~June 30, 2022, the Company had an accumulated deficit of $~~216.5~~238.8 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these interim condensed consolidated financial statements, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months. The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

Impact of the COVID-19 Pandemic

In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was initially reported ~~to have surfaced in Wuhan, China. Since~~and since then, COVID-19 ~~coronavirus~~ has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the U.S. government-imposed travel restrictions on travel between the United States, Europe and certain other countries. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on hospitals, businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, prices have increased and facilities and production have been suspended. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain.

The COVID-19 pandemic has impacted and may continue to impact personnel at third-party manufacturing facilities or the availability or cost of materials, which would disrupt the Company’s supply chain. It also has affected and may continue to affect the Company’s ability to enroll patients in and timely complete its ongoing clinical trials of SQZ-PBMC-HPV, SQZ-AAC-HPV and SQZ-eAPC-HPV and delay the initiation of future clinical trials, disrupt regulatory activities or have other adverse effects on its business and operations.

The Company is monitoring the potential impact of the COVID-19 pandemic on its business and financial statements. To date, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these interim condensed consolidated financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of

Table of Contents

operations, financial condition and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects.

~~Table of Contents~~

Basis of Presentation

The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, SQZ Biotechnologies Security Corporation, SQZ Biotech HK Limited and SQZ Biotech (Shanghai) Co., Ltd. All intercompany accounts and transactions have been eliminated in consolidation.

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying ~~unaudited~~condensed consolidated financial statements as of ~~March 31,~~June 30, 2022 and for the three and six months ended ~~March 31,~~June 30, 2022 and 2021 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The accompanying condensed consolidated balance sheet as of December 31, 2021 was derived from audited financial statements but does not include all disclosures required by GAAP. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 16, 2022. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s consolidated financial position as of ~~March 31,~~June 30, 2022, the consolidated results of operations for the three and six months ended ~~March 31,~~June 30, 2022 and 2021, and the consolidated cash flows for ~~three~~the six months ended ~~March 31,~~June 30, 2022 and 2021 have been made. The Company’s consolidated results of operations for the three and six months ended ~~March 31,~~June 30, 2022 are not necessarily indicative of the results of operations that may be expected for the full year or any other subsequent interim period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, judgments and methodologies as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.

Segment Information

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is developing methods of engineering cell function and therapies for the treatment of patients across a range of indications. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance.

Revenue Recognition for Government Grants

The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company’s ongoing operations, the Company classifies the recognized funding received as revenue. Revenue from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. The Company submits a budget, which outlines the expected project costs, to the funding government agency on a periodic basis. If the government agency approves the project proposed by the Company, the government agency generally funds the project upon receipt of the support for the costs incurred. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded as unbilled receivables, a component of prepaid expenses and other current assets, in the consolidated balance sheet. The related costs incurred by the Company are included in research and development expense in the Company’s consolidated statements of operations and

Table of Contents

comprehensive loss. In certain cases, the Company may obtain grants from an economic development agency that are not central to the Company's ongoing business. The income from these grants is recognized within Other income (expense), net in the consolidated statement of operations and comprehensive loss when there is reasonable assurance of recoverability.

Recently Issued Accounting Pronouncements

The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will

~~Table of Contents~~

result in the earlier recognition of credit losses, if any. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”), which provides additional implementation guidance on the previously issued ASU 2016-13. For the Company, this guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements, however the Company does not expect that the standard will have a material impact on its consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions, including the approach for intraperiod tax allocation, the accounting for income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. The Company adopted this standard as of January 1, 2022 and the standard did not have a material impact on its consolidated financial statements.

In November 2021, the FASB issued ASU 2021-10, Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain disclosures when they have 1) received government assistance and 2) use a grant or contribution accounting model by analogy to other accounting guidance. The Company adopted this standard as of January 1, 2022 and the standard did not have a material impact on its consolidated financial statements.

3. Fair Value Measurements

The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands):


	FAIR VALUE MEASUREMENTS AT MARCH 31, 2022 USING:								FAIR VALUE MEASUREMENTS AT JUNE 30, 2022 USING:
	LEVEL 1		LEVEL 2		LEVEL 3		TOTAL		LEVEL 1		LEVEL 2		LEVEL 3		TOTAL
Assets:
Cash equivalents:
Money market funds	$	121,958	$	—	$	—	$	121,958	$	104,215	$	—	$	—	$	104,215
	$	121,958	$	—	$	—	$	121,958	$	104,215	$	—	$	—	$	104,215


	FAIR VALUE MEASUREMENTS AT DECEMBER 31, 2021 USING:
	LEVEL 1		LEVEL 2		LEVEL 3		TOTAL
Assets:
Cash equivalents:
Money market funds	$	142,547	$	—	$	—	$	142,547
	$	142,547	$	—	$	—	$	142,547

Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There were 0 changes to the valuation methods during the ~~three~~six months ended ~~March 31,~~June 30, 2022.The Company evaluates transfers between levels at the end of each reporting period. There were 0 transfers between levels during the ~~three~~six months ended ~~March 31,~~June 30, 2022.

4. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

MARCH 31,

DECEMBER 31,

2022

2021

Machinery and equipment

$
6,536

$
6,659

Leasehold improvements

579

579

Furniture and fixtures

318

319

$
7,433

$
7,557

Less: Accumulated depreciation and amortization

(4,548
)

(4,511
)

$
2,885

$
3,046


	JUNE 30,			DECEMBER 31,
	2022			2021
Machinery and equipment	$	6,615		$	6,659
Leasehold improvements		579			579
Furniture and fixtures		319			319
	$	7,513		$	7,557
Less: Accumulated depreciation and amortization		(4,830	)		(4,511	)
	$	2,683		$	3,046

Depreciation and amortization expense for each of the three months ended ~~March 31,~~June 30, 2022 and 2021 was $0.3 million. Depreciation and amortization expense for each of the six months ended June 30, 2022 and 2021 was $0.6 million.

5. Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	MARCH 31,		DECEMBER 31,		JUNE 30,		DECEMBER 31,
	2022		2021		2022		2021

Accrued external research, development and manufacturing costs	$	5,168	$	2,156	$	5,745	$	2,156
Accrued employee compensation and benefits		1,349		3,040		2,309		3,040
Other		2,009		1,614		1,657		1,614
	$	8,526	$	6,810	$	9,711	$	6,810

6. Stock-Based Compensation

The following table summarizes the Company’s stock option activity since December 31, 2021:


	NUMBER OF SHARES			WEIGHTED- AVERAGE EXERCISE PRICE		WEIGHTED- AVERAGE REMAINING CONTRACTUAL TERM		INTRINSIC VALUE		NUMBER OF SHARES			WEIGHTED- AVERAGE EXERCISE PRICE		WEIGHTED- AVERAGE REMAINING CONTRACTUAL TERM		INTRINSIC VALUE
						(in years)		(in thousands)							(in years)		(in thousands)
Outstanding at December 31, 2021		4,339,523		$	9.75		7.68	$	8,823		4,339,523		$	9.75		7.68	$	8,823
Granted		1,962,387			6.46						2,485,987			5.80
Exercised		(14,757	)		1.95						(14,757	)		1.95
Forfeited or canceled		(195,726	)		10.85						(232,215	)		10.83
Outstanding at March 31, 2022		6,091,427		$	8.67		8.02	$	1,298
Vested and expected to vest at March 31, 2022		6,091,427		$	8.67		8.02	$	1,298
Options exercisable at March 31, 2022		2,306,348		$	7.23		6.03	$	1,247
Outstanding at June 30, 2022											6,578,538		$	8.24		7.93	$	482
Vested and expected to vest at June 30, 2022											6,578,538		$	8.24		7.93	$	482
Options exercisable at June 30, 2022											2,608,968		$	7.74		6.05	$	482

Stock-Based Compensation Expense

Stock-based compensation expense related to stock options was classified in the consolidated statements of operations as follows (in thousands):


	THREE MONTHS ENDED MARCH 31,				THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2022		2021		2022		2021		2022		2021
Research and development expenses	$	655	$	562	$	874	$	683	$	1,529	$	1,247
General and administrative expenses		1,292		1,019		1,433		1,146		2,725		2,165
	$	1,947	$	1,581	$	2,307	$	1,829	$	4,254	$	3,412

Table of Contents

As of ~~March 31,~~June 30, 2022, total unrecognized stock-based compensation expense related to unvested stock-based awards was $~~22.7~~21.5 million, which is expected to be recognized over a weighted-average period of ~~3.1~~2.9 years.

9. Leases

Table of Contents

As of ~~March 31,~~June 30, 2022, the Company leases its office and laboratory facilities under a non-cancelable operating lease entered into in December 2018, which included lease incentives, payment escalations and rent holidays. In addition, the Company has an agreement entered into in April 2019 with a contract manufacturing supplier that is considered an embedded lease because the Company has substantially all the economic benefits of the related asset and can direct its use. The Company had not entered into any financing leases or any short-term operating leases as of ~~March 31,~~June 30, 2022 and December 31, 2021.

The components of lease cost and other information for the Company’s lease portfolio were as follows (in thousands, except term and discount rate amounts):


	THREE MONTHS ENDED MARCH 31,				THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2022		2021		2022		2021		2022		2021
Lease cost:
Operating lease cost	$	3,760	$	3,261	$	3,760	$	3,273	$	7,520	$	6,534
Variable lease cost		557		325		414		679		970		1,003
	$	4,317	$	3,586	$	4,174	$	3,952	$	8,490	$	7,537

~~Table of Contents~~


	MARCH 31, 2022			DECEMBER 31, 2021			JUNE 30, 2022			DECEMBER 31, 2021
Other information:
Weighted-average remaining lease term (in years)		5.9			6.2			5.7			6.2
Weighted-average discount rate		7.6	%		7.6	%		7.6	%		7.6	%

Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):


	THREE MONTHS ENDED MARCH 31,				SIX MONTHS ENDED JUNE 30,
	2022		2021		2022		2021
Cash paid for amounts included in the measurement of operating lease liabilities:
Operating cash flows from operating leases	$	3,657	$	3,132	$	7,403	$	6,249

10. License and Collaboration Agreements

2017 License and Collaboration Agreement with Roche

In April 2017, the Company entered into a second license and collaboration agreement with Roche (the “2017 Roche Agreement”) to allow Roche to use the Company’s Cell Squeeze technology to enable gene editing of immune cells to discover new targets in cancer immunotherapy. The 2017 Roche Agreement included several licenses granted by Roche to the Company and by the Company to Roche in order to conduct a specified research program in accordance with a specified research plan. In the first quarter of 2022, the ~~Company received notice that the~~ 2017 Roche Agreement was terminated and all active work streams under the 2017 Roche Agreement were concluded. As of December 31, 2021, the Company determined that it expected to incur no additional costs to satisfy the remaining performance obligations under the 2017 Roche Agreement and all remaining deferred revenue was recognized as of that date. There was 0 revenue recorded under this agreement during the three and six months ended ~~March 31,~~June 30, 2022.

During the three and six months ended ~~March 31,~~June 30, 2021, the total costs expected to be incurred to satisfy the performance obligation under the 2017 Roche Agreement decreased by $0.1 million and $0.3 ~~million.~~million, respectively. The Company recognized revenue of $~~0.6~~0.2 million and $0.8 million during the three and six months ended ~~March 31, 2021.~~June 30, 2021, respectively.

2018 License and Collaboration Agreement with Roche

In October 2018, the Company entered into a license and collaboration agreement with Roche (the “2018 Roche Agreement”) to jointly develop certain products based on mononuclear antigen presenting cells (“APCs”), including human ~~papilloma virus~~papillomavirus (“HPV”), using the SQZ APC platform for the treatment of oncology indications. The Company granted Roche a non-exclusive license to its intellectual property, and Roche granted the Company a non-exclusive license to its and its affiliates’ intellectual property for the purpose of performing research activities. In connection with this agreement, the parties terminated an earlier agreement. The 2018 Roche Agreement has a term that extends until all royalty, profit-share and other payment obligations expire or have been satisfied. Roche has the right to terminate the 2018 Roche Agreement, in whole or on a product-by-product basis, upon a specified amount of notice to the

Table of Contents

Company. The Company or Roche may terminate the agreement if the other party fails to cure its material breach within a specified period after receiving notice of such breach.

Under the 2018 Roche Agreement, Roche was granted option rights to obtain an exclusive license to develop APC products or products derived from the collaboration programs on a product-by-product basis. These option rights are exercisable upon the achievement of clinical Phase 1 proof of concept and expire, if unexercised, as of a date specified in the agreement. In addition, Roche was granted an option right to obtain an exclusive license to develop a Tumor Cell Lysate (“TCL”) product. This option right is exercisable upon the achievement of clinical proof of concept and expires, if unexercised, as of a date specified in the agreement. For each of the APC products and TCL product, once Roche exercises its option and pays a specified incremental amount ranging from $15.0 million to $50.0 million for APC products and of $100.0 million for the TCL product, Roche will receive worldwide, exclusive commercialization rights for the licensed products, subject to the Company’s alternating option to retain U.S. APC commercialization rights. The Company will retain worldwide commercialization rights to any APC products or the TCL product for which Roche elects not to exercise its applicable option. For the first APC product that Roche exercises its option, Roche will receive worldwide, exclusive commercialization rights for the licensed product. On a product-by-product basis for the APC products, after the first product option is exercised by Roche and for every other product for which Roche exercises its option, the Company will retain an option to obtain the exclusive commercialization rights in the United States. Upon exercise of the TCL option by Roche, (i) the Company will be entitled to receive the aforementioned

~~Table of Contents~~

milestone payment of $100.0 million and (ii) profits from the TCL product will be shared equally by the Company and Roche. Through ~~March 31,~~June 30, 2022, Roche had not exercised any of its options under the 2018 Roche Agreement.

Under the 2018 Roche Agreement, the Company received an upfront payment of $45.0 million and is eligible to receive (i) reimbursement of a mid-double-digit percentage of its development costs; (ii) aggregate milestone payments on a product-by-product basis of up to $1.6 billion upon the achievement of specified milestones, consisting of up to $217.0 million of development milestone payments, up to $240.0 million of regulatory milestone payments and up to $1.2 billion of sales milestone payments; and (iii) tiered royalties on annual net sales of APC and TCL products licensed under the agreement, as described below. The Company received the upfront payment of $45.0 million in October 2018 upon execution of the agreement. In addition, during the second quarter of 2019, the Company received a payment of $10.0 million following the achievement of the first development milestone under the 2018 Roche Agreement related to submission by the Company of preclinical data to the U.S. Food and Drug Administration (“FDA”). During the first quarter of 2020, the Company received a payment of $20.0 million following the achievement of the second development milestone under the 2018 Roche Agreement related to first-patient dosing in a Phase 1 clinical trial. In the first quarter of 2022, the Company received a milestone payment of $3.0 million having achieved in the fourth quarter of 2021 the following: (i) the endorsement by an independent panel that it could advance its SQZ-PBMC-HPV clinical trial to combination therapy using checkpoint inhibitors and (ii) the initiation of that therapy.

Roche will pay tiered royalties based on annual net sales of APC and TCL products. If Roche exercises its option to obtain a license to commercialize an APC product, Roche will pay the Company tiered royalties on annual net sales of that licensed product at rates ranging from a mid-single-digit percentage to a mid-teens percentage, depending on net sales of the product. If the Company exercises its option to obtain a license to commercialize an APC product in the United States, it will pay Roche tiered royalties on annual net sales of that licensed product at rates ranging from a mid-single-digit percentage to a mid-teens percentage, depending on net sales of the product in the United States. For APC products selected by Roche, rather than mutually, Roche will pay the Company royalties on annual net sales of that licensed product at rates ranging from a mid-single-digit percentage to a high single-digit percentage, depending on net sales of the product. For APC products that are selected mutually and for which the Company has not exercised its option to commercialize the product in the United States, Roche will pay the Company tiered royalties on annual net sales of that licensed product at a rate ranging from a high single-digit percentage to a mid-teens percentage, depending on net sales of the product. For TCL products, Roche will pay the Company tiered royalties on the aggregate net sales of all TCL products at rates ranging from either a mid-single digit percentage to a percentage in the low twenties, with the caveat that the rates for sales in the United States may instead range from a low-teens percentage to a percentage in the mid-twenties, depending on whether and when the Company opts out of sharing certain profits and costs of commercializing the TCL product in the United States with Roche.

The Company identified three performance obligations at the outset of the 2018 Roche Agreement: (1) the license to the Company’s intellectual property, the research and development activities related to HPV through Phase 1 clinical trials under a specified research plan, and the manufacturing of the Company’s SQZ APC platform and equipment in order to support the HPV research plan (the “first performance obligation”); (2) the license to the Company’s intellectual property and the research and development activities on next-generation APCs (the “second performance obligation”); and (3) the license to the Company’s intellectual property and the research and development activities on TCL (the “third performance obligation”).

During the fourth quarter of 2019, the Company evaluated its overall program priorities and determined that it would continue to focus its resources on progressing the specified APC programs related to the 2018 Roche Agreement as well as its Activating Antigen Carriers (“AAC”) and Tolerizing Antigen Carriers (“TAC”) platforms. As a result of its continuing focus on these specific programs, the Company reduced the level of priority of the TCL research activities under the 2018 Roche Agreement and expects to perform such TCL

Table of Contents

research activities over a longer time period than as originally expected under the specified research plan of the agreement. Since the fourth quarter of 2019, the Company has classified $9.2 million as non-current deferred revenue, which will remain unrecognized as revenue until TCL research activities resume or the 2018 Roche Agreement is modified by the Company and Roche.

The Company separately recognizes revenue associated with each of the three performance obligations as the research, development and manufacturing services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy each performance obligation. The transfer of control to the customer occurs over the time period that the research and development services are to be provided by the Company, and this cost-to-cost method is, in management’s judgment, the best measure of progress towards satisfying each performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability in the Company’s consolidated balance sheet and will be recognized over the remaining research and development period until each performance obligation is satisfied.

During the three and six months ended ~~March 31,~~June 30, 2022 and 2021, there were 0 significant changes in the total estimated costs expected to be incurred to satisfy the performance obligations under the 2018 Roche Agreement. The Company recognized revenue of $~~2.9~~3.0 million and $~~4.9~~4.3 million during the three months ended ~~March 31,~~June 30, 2022 and 2021, respectively, under this agreement. The Company recognized revenue of $5.9 million and $9.1 million during the six months ended June 30, 2022 and 2021, respectively, under this agreement. As of ~~March 31,~~June 30, 2022, the Company recorded as a contract liability deferred revenue related to the 2018 Roche Agreement of $~~18.3~~15.3 million, of which $~~9.1~~6.1 million

~~Table of Contents~~

was a current liability. As of ~~March 31,~~June 30, 2022, the research and development services related to the performance obligations were expected to be performed over a remaining period of ~~nine~~six months. As of December 31, 2021, the Company recorded as a contract liability deferred revenue related to the 2018 Roche Agreement of $21.2 million, of which $12.0 million was a current liability.

As of ~~March 31,~~June 30, 2022 and December 31, 2021, the expected remaining period of performance of the Company’s research and development services related to the third performance obligation was not determinable, and it will not become determinable until TCL research activities resume or the 2018 Roche Agreement is modified by the Company and Roche.

Contract Liability

The changes in the total contract liability (deferred revenue) balances related to the Company’s license and collaboration agreements were as follows (in thousands):


	THREE MONTHS ENDED MARCH 31,						THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2022			2021			2022			2021			2022			2021
Balance at beginning of period	$	21,203		$	45,201		$	18,334		$	39,747		$	21,203		$	45,201
Recognition of deferred revenue		(2,869	)		(5,454	)		(3,008	)		(4,539	)		(5,877	)		(9,993	)
Other								—			100			—			100
Balance at end of period	$	18,334		$	39,747		$	15,326		$	35,308		$	15,326		$	35,308

11. Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):


	THREE MONTHS ENDED MARCH 31,						THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2022			2021			2022			2021			2022			2021
Numerator:
Net loss	$	(21,038	)	$	(15,399	)	$	(22,236	)	$	(19,070	)	$	(43,274	)	$	(34,469	)
Denominator:
Weighted-average common shares outstanding, basic and diluted		28,145,036			26,264,019			28,367,355			27,919,647			28,256,810			27,100,817
Net loss per share attributable to common stockholders, basic and diluted	$	(0.75	)	$	(0.59	)	$	(0.78	)	$	(0.68	)	$	(1.53	)	$	(1.27	)

The Company’s potential dilutive securities, which consist of common stock options have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares

Table of Contents

outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

THREE MONTHS ENDED
MARCH 31,

2022

2021

Stock options to purchase common stock

6,091,427

4,710,746

6,091,427

4,710,746


	THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2022		2021		2022		2021
Stock options to purchase common stock		6,578,538		4,571,645		6,578,538		4,571,645
		6,578,538		4,571,645		6,578,538		4,571,645

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission, or SEC, on March 16, 2022 (the “2021 Form 10-K”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk ~~Factors��~~Factors” section of our 2021 Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

We are a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases, and other serious conditions. The company was founded on the therapeutic potential of Cell Squeeze® technology, our proprietary technology which allows for rapid delivery of a variety of cargo into different cell types. We aim to create multiple cell therapies that drive the immune system to combat diseases.

In oncology, we are developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. We believe that by engineering physiological antigen presentation signals in subsets of peripheral blood cells that act on immune priming pathways, we have the potential to develop cell therapies that are designed to be potent drivers of tumor-specific immunity, well-tolerated, administered without lymphodepleting preconditioning or hospitalization, and produced in under 24 hours. We have three oncology candidates in clinical trials across our SQZ® Antigen Presenting Cell, or APC, SQZ® enhanced APC, or eAPC, and SQZ® Activating Antigen Carrier, or AAC, cell therapy platforms. In our autoimmune diseases portfolio, we are developing our SQZ® Tolerizing Antigen Carrier, or TAC, cell therapy platform with the aim to restore immune tolerance to self-antigens or other autoimmune disease-associated antigens that are central to disease pathogenesis.

In 2021, we executed on several key areas of our pipeline and advanced our APC platform objectives. As of December 31, 2021, we have dosed 20 patients in our Phase 1 trial for our lead APC candidate, SQZ-PBMC-HPV, in HPV16+ advanced solid tumors. We reported interim data from the first three monotherapy dose-escalation cohorts at the 2021 American Society of Clinical Oncology, or ASCO, Annual Meeting, and presented interim safety, biomarker, and clinical data from the highest dose SQZ-PBMC-HPV monotherapy cohort at the 2021 European Society for Medical Oncology Immuno-Oncology, or ESMO-IO, Congress. Key observations from the reported data include, as of a cutoff date of October 8, 2021 (n=18 patients):

We have advanced our trial to evaluate SQZ-PBMC-HPV in combination with checkpoint inhibitor therapies, and are continuing to enroll patients in the highest dose monotherapy cohort. We are targeting additional data in the second half of 2022. In April 2022, the U.S. Food and Drug Administration, or FDA, granted Fast Track Designation to SQZ-PBMC-HPV for the treatment of HPV16+ advanced or metastatic solid tumors.

We have continued to build upon the progress of our SQZ® APC platform through the development of the novel SQZ® eAPC platform. Our lead eAPC product candidate leverages the added capabilities and functionality of multiple antigen presentation and immunological signals achieved through multiplexed mRNA delivery to diverse immune cell types. In January 2022, we received allowance to proceed with clinical trials from the FDA under our Investigational New Drug, or IND, application for SQZ-eAPC-HPV, our lead eAPC candidate engineered with HPV16 antigens and costimulatory signals. We ~~plan to initiate~~initiated the SQZ-eAPC-HPV trial, the COMMANDER-001 Phase 1/2 study, in patients with HPV16+ advanced solid tumors in the first half of 2022. We anticipate announcing initial interim data from this study in the second half of 2022. In addition to our efforts in the oncology field, we are also continuing to advance development of the eAPC platform in the infectious diseases field.

In 2021, we received allowance to proceed with clinical trials from the FDA under our IND for SQZ-AAC-HPV, our lead AAC product candidate derived from red blood cells engineered with tumor-specific antigens. We are currently enrolling monotherapy cohorts as part of the Phase 1 ENVOY-001 trial to assess safety and tolerability as well as secondary outcome measures of the investigational SQZ-AAC-HPV therapy in HPV16+ advanced solid tumors, and plan to announce initial interim data in the second half of 2022.

We are also advancing our SQZ® TAC platform focused on creating novel and proprietary cell therapies as it relates to modulating or restoring immune tolerance. We have selected Celiac disease as the first proposed autoimmune indication for SQZ® TAC platform development. We believe the evidence of a causal disease antigen and T-cell driven pathology, and the substantial unmet need for a

tolerizing treatment option provide a compelling opportunity for us to pursue Celiac disease. We presented characterization of TAC-mediated mechanisms of antigen-specific tolerance in preclinical models at the 2021 Federation of Clinical Immunology Societies, or FOCIS, Meeting. We anticipate further development of our TAC-Celiac candidate through IND-enabling studies in 2022 to support an IND submission in the first half of 2023, and, in parallel, are planning to use our proprietary, point-of-care manufacturing system for the production of the clinical batches.

Since our inception, we have focused substantially all of our resources on building our Cell Squeeze technology, establishing and protecting our intellectual property portfolio, conducting research and development activities, developing our manufacturing process and manufacturing product candidate materials, preparing for and initiating clinical trials of our product candidates, organizing and staffing our company, business planning, raising capital and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales. Through ~~March 31,~~June 30, 2022, we have funded our operations primarily with upfront and milestone payments received under our collaboration agreements with Hoffman La Roche Inc. and F. Hoffman La Roche Ltd. (together, "Roche",) and with proceeds from equity and debt offerings, most recently from our initial public offering, or IPO, and follow-on public offering of common stock, or the Follow-on Offering. During the three and six months ended June 30, 2022, we raised $3.1 million, utilizing an “at-the-market” offering facility, pursuant to which we sold 958,663 shares of our common stock.

Since our inception, we have incurred significant operating losses. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. We reported a net loss of ~~$21.0~~$43.3 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022. As of ~~March 31,~~June 30, 2022, we had an accumulated deficit of ~~$216.5~~$238.8 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:

We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, and distribution.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Currently, market conditions in the biotechnology sector are challenging due to ongoing global and economic uncertainties. Accordingly, we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we would have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates.

Because of the numerous risks and uncertainties associated with cell therapy product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

The COVID-19 pandemic and government measures taken in response have had a significant impact, both direct and indirect, on hospitals, businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, prices have increased and facilities and production have been suspended. The future progression of the pandemic and its effects on our business and operations are uncertain.

The COVID-19 pandemic has impacted and may continue to impact personnel at third-party manufacturing facilities or the availability or cost of materials, which would disrupt our supply chain. It also has affected and may continue to affect our ability to enroll patients in and timely complete our ongoing clinical trials of SQZ-PBMC-HPV, SQZ-AAC-HPV and SQZ-eAPC-HPV and delay the initiation of future clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. For example, we have experienced delays in receiving supplies of raw materials for our preclinical activities due to the impact of COVID-19 on our suppliers’ ability to timely manufacture these materials, and we have experienced an increase in the transportation cost of our product candidates due to the decreased availability of commercial flights. In addition, we have experienced delays in opening clinical trial sites and sites that are open may also have challenges enrolling patients. Further, staff shortages, including staff that are required to conduct certain testing, such as biopsies, at our clinical sites or at third-party vendors have resulted in delays in site initiations and in some tests not being properly or timely performed or being delayed. In response to the public health directives and to help reduce the risk to our employees, we took precautionary measures, including implementing work-from-home policies for our administrative employees and staggered work times for our lab employees. We plan to continue to implement restrictive measures and are assessing when and how to resume normal operations. The effects of the public health directives and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines and future clinical trials, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, results of operations and financial condition, including our ability to obtain financing.

The pandemic and related uncertainties have already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds to support our operations. Moreover, the pandemic has significantly impacted inflation and economies worldwide and could result in adverse effects on our business and operations. We are monitoring the potential impact of the COVID-19 pandemic on our business and financial statements. To date, we have not incurred impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in our interim condensed consolidated financial statements. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and people. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, financial condition, and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects.

To date, we have not generated any revenue from product sales and do not expect to do so for the next several years. All of our revenue to date has been derived from three collaboration agreements with Roche, and, to a lesser extent, from government grants.

If our development efforts for our product candidates are successful and result in regulatory approval, or in license or additional collaboration agreements with third parties, we may generate revenue in the future from product sales, payments from additional collaboration or license agreements that we may enter into with third parties, or any combination thereof. We expect that our revenue for the next several years will be derived primarily from our collaboration agreements with Roche as well as any additional collaborations that we may enter into in the future. We cannot provide assurance as to the timing of future milestone or royalty payments or that we will receive any of these payments at all.

In April 2017, we entered into a second license and collaboration agreement with Roche (the “2017 Roche Agreement”) to allow Roche to use our Cell Squeeze® technology to enable gene editing of immune cells to discover new targets in cancer immunotherapy. The 2017 Roche Agreement included several licenses granted by Roche to us and by us to Roche in order to conduct a specified research program in accordance with a specified research plan. In the first quarter of 2022, ~~we received notice that~~ the 2017 Roche Agreement was terminated and all active work

streams under the 2017 Roche Agreement were concluded. As of December 31, 2021, we had determined

that we expected to incur no additional costs to satisfy the remaining performance obligations under the 2017 Roche Agreement and all remaining deferred revenue was recognized as of that date. There was no revenue recorded under this agreement during the three and six months ended ~~March 31,~~June 30, 2022.

During the three and six months ended ~~March 31,~~June 30, 2021, the total costs expected to be incurred to satisfy the performance obligation under the 2017 Roche Agreement decreased by $0.1 million and $0.3 ~~million.~~million, respectively. We recognized revenue of ~~$0.6~~$0.2 million and $0.8 million during the three and six months ended ~~March 31, 2021.~~June 30, 2021, respectively.

In October 2018, we entered into a license and collaboration agreement with Roche, or the 2018 Roche Agreement, to jointly develop certain products based on mononuclear antigen presenting cells, or APCs, including human ~~papilloma virus,~~papillomavirus, or HPV, using our SQZ APC platform for the treatment of oncology indications. We granted Roche a non-exclusive license to our intellectual property, and Roche granted us a non-exclusive license to its and its affiliates’ intellectual property for the purpose of performing research activities. In connection with this agreement, the parties terminated an earlier agreement.

Under the 2018 Roche Agreement, Roche was granted option rights to obtain an exclusive license to develop APC products or products derived from the collaboration programs on a product-by-product basis and to develop a Tumor Cell Lysate, or TCL, product. For each of the APC products and TCL product, once Roche exercises its option and pays a specified incremental amount, Roche will receive worldwide, exclusive commercialization rights for the licensed products. Through ~~March 31,~~June 30, 2022, Roche had not exercised any of its options under the 2018 Roche Agreement.

Under the 2018 Roche Agreement, we received an upfront payment of $45.0 million and are eligible to receive (i) reimbursement of a mid-double-digit percentage of our development costs; (ii) aggregate milestone payments on a product-by-product basis of up to $1.6 billion upon the achievement of specified milestones, consisting of up to $217.0 million of development milestone payments, up to $240.0 million of regulatory milestone payments and up to $1.2 billion of sales milestone payments; and (iii) tiered royalties on annual net sales of APC and TCL products licensed under the agreement at specified rates ranging from a mid-single-digit percentage to a percentage in the mid-twenties. We received the upfront payment of $45.0 million in October 2018 upon execution of the agreement. In addition, during the second quarter of 2019, we received a payment of $10.0 million following the achievement of the first development milestone under the 2018 Roche Agreement related to submission by us of preclinical data to the FDA. During the first quarter of 2020, we received a payment of $20.0 million following the achievement of the second development milestone under the 2018 Roche Agreement related to first-patient dosing in a Phase 1 clinical trial. In the first quarter of 2022, we received a milestone payment of $3.0 million having achieved in the fourth quarter of 2021 the following: (i) the endorsement by an independent panel that we could advance our SQZ-PBMC-HPV clinical trial to combination therapy using checkpoint inhibitors and (ii) the initiation of that therapy.

We identified three performance obligations at the outset of the 2018 Roche Agreement: (1) the license to our intellectual property, the research and development activities related to HPV through Phase 1 clinical trials under a specified research plan, and the manufacturing of our SQZ APC platform and equipment in order to support the HPV research plan (the “first performance obligation”); (2) the license to our intellectual property and the research and development activities on next-generation APCs (the “second performance obligation”); and (3) the license to our intellectual property and the research and development activities on TCL (the “third performance obligation”).

In addition, we determined that the upfront payment of $45.0 million as well as the reimbursable costs of $10.8 million estimated by us constituted the entirety of the consideration to be included in the transaction price. This transaction price of $55.8 million was initially allocated to the three performance obligations based on the relative standalone selling price of each obligation. The potential milestone payments that we may be eligible to receive were excluded from the transaction price at the outset of the arrangement. We reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, we will adjust our estimate of the transaction price.

We separately recognize revenue associated with each of the three performance obligations as the research, development and manufacturing services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy each performance obligation. The amounts received from Roche that have not yet been recognized as revenue are deferred as a contract liability in our consolidated balance sheet and will be recognized over the remaining research and development period until each performance obligation is satisfied.

During the fourth quarter of 2019, we evaluated our overall program priorities and determined that we would continue to focus our resources on progressing the specified APC programs related to the 2018 Roche Agreement as well as our SQZ AAC and SQZ TAC platforms. As a result of our continuing focus on these specific programs, we reduced the level of priority of the TCL research activities under the 2018 Roche Agreement and expect to perform such TCL research activities over a longer time period than as originally expected under the specified research plan of the agreement. Since the fourth quarter of 2019, we have classified $9.2 million as

non-current deferred revenue, which will remain unrecognized as revenue until TCL research activities resume or the 2018 Roche Agreement is modified by us and Roche.

During the three months ended ~~March 31,~~June 30, 2022 and 2021, there were no significant changes in the total estimated costs expected to be incurred to satisfy the performance obligations under the 2018 Roche Agreement. We recognized revenue of ~~$2.9~~$3.0 million and ~~$4.9~~$4.3 million during the three months ended ~~March 31,~~June 30, 2022 and 2021, respectively, under this agreement. We recognized revenue of $5.9 million and $9.1 million during the six months ended June 30, 2022 and 2021, respectively, under this agreement. As of ~~March 31,~~June 30, 2022, we recorded as a contract liability deferred revenue related to the 2018 Roche Agreement of ~~$18.3~~$15.3 million, of which ~~$9.1~~$6.1 million was a current liability. As of ~~March 31,~~June 30, 2022, the research and development services related to the performance obligations were expected to be performed over a remaining period of ~~nine~~six months.

As of ~~March 31,~~June 30, 2022, the expected remaining period of performance of our research and development services related to the third performance obligation was not determinable, and it will not become determinable until TCL research activities resume or the 2018 Roche Agreement is modified by us and Roche.

We generate revenue from a government contract with the National Institutes of Health (NIH), which reimburses us for certain allowable costs for funded projects, plus an agreed upon fee. Revenue from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded as unbilled receivables, a component of prepaid expenses and other current assets, in our consolidated balance sheet.

Research and development expenses consist primarily of costs incurred for our research activities, including development of our product candidates and costs incurred under our collaboration arrangements with Roche, which include:

We expense research and development costs as incurred. Nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable.

Our direct research and development expenses are tracked on a program-by-program basis and consist of external costs and fees paid to consultants, contractors, CMOs and CROs in connection with our preclinical and clinical development and manufacturing activities. Such program costs also include the external costs of laboratory and consumable materials and costs of raw materials that are directly attributable to and incurred for any single program. We do not allocate employee costs, costs associated with our platform development and discovery efforts, payments made under third-party licensing agreements, costs of laboratory supplies and consumable materials that are not directly attributable to any single program, and facilities expenses, including rent, depreciation and other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform technology and, as such, are not separately classified.

Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned preclinical and clinical development activities in the near term and in the future, particularly should Roche determine not to exercise its options and we decide to continue clinical development of a product candidate. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates. The successful development of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following:

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. In addition, we may never succeed in obtaining regulatory approval for any of our product candidates.

General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.

Other income (expense), net consists of miscellaneous income and expense unrelated to our core operations.

Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credit carryforwards will not be realized.

The following table summarizes our results of operations for the three months ended ~~March 31,~~June 30, 2022 and 2021:

Collaboration revenue decreased by ~~$2.6~~$1.5 million to ~~$2.9~~$3.0 million for the three months ended ~~March 31,~~June 30, 2022, compared to ~~$5.5~~$4.5 million for the three months ended ~~March 31,~~June 30, 2021. The decrease in revenue was primarily due to the following:

Grant revenue increased by $0.2 million. We were awarded a government grant by the NIH at the end of the first quarter of 2022 and began performing services under this grant during the second quarter of 2022.


	THREE MONTHS ENDED MARCH 31,			THREE MONTHS ENDED JUNE 30,
	2022	2021	CHANGE	2022	2021	CHANGE
	(in thousands)			(in thousands)
Direct research and development expenses by program:
SQZ-PBMC-HPV	$1,903	$4,189	$(2,286)	$2,315	$2,938	$(623)
SQZ-AAC-HPV	1,357	1,059	298	1,530	1,051	479
SQZ-eAPC-HPV	3,332	1,029	2,303	2,723	4,185	(1,462)
Other programs	2,491	1,885	606	3,855	2,620	1,235
Unallocated research and development expenses:
Personnel related (including stock-based compensation)	5,359	4,199	1,160	5,908	4,475	1,433
Facility related	1,411	1,142	269	1,310	1,423	(113)
Laboratory and consumable materials	325	262	63	320	335	(15)
Platform-related external services and other	832	975	(143)	799	655	144
Total research and development expenses	$17,010	$14,740	$2,270	$18,760	$17,682	$1,078

Research and development expenses increased by ~~$2.3~~$1.1 million to ~~$17.0~~$18.8 million for the three months ended ~~March 31,~~June 30, 2022, from ~~$14.7~~$17.7 million for the three months ended ~~March 31,~~June 30, 2021. The net increase was primarily due to the following:


	THREE MONTHS ENDED MARCH 31,			THREE MONTHS ENDED JUNE 30,
	2022	2021	CHANGE	2022	2021	CHANGE
	(in thousands)			(in thousands)
Personnel related (including stock-based compensation)	$3,481	$2,909	$572	$3,626	$3,025	$601
Professional, consultant and patent related costs	1,745	1,524	221	1,356	1,165	191
Facility related and other	1,686	1,687	(1)
Facility related and other costs				1,976	1,743	233
Total general and administrative expenses	$6,912	$6,120	$792	$6,958	$5,933	$1,025

General and administrative expenses increased by ~~$0.8~~$1.1 million during the three months ended ~~March 31,~~June 30, 2022 to ~~$6.9~~$7 million, compared to ~~$6.1~~$5.9 million for the three months ended ~~March 31,~~June 30, 2021. The increase was primarily due to:

Interest income for the three months ended June 30, 2022 and 2021 was $0.2 million and $11 thousand, respectively. The increase in interest income was due to the increase in average interest rates during the respective periods.

Other income (expense), net for the three months ended June 30, 2022 was $0.1 million. The other income of $0.1 million for the three months ended June 30, 2022 was primarily related to a grant received from a Massachusetts economic development and investment agency. Other income (expense), net for the three months ended June 30, 2021 was insignificant.

The following table summarizes our results of operations for the six months ended June 30, 2022 and 2021:

Collaboration revenue decreased by $4.1 million to $5.9 million for the six months ended June 30, 2022, compared to $10.0 million for the three months ended June 30, 2021. The decrease in revenue was primarily due to the following:

Research and development expenses increased by $3.4 million to $35.8 million for the six months ended June 30, 2022 from $32.4 million for the six months ended June 30, 2021. The net increase was primarily due to the following:

General and administrative expenses increased by $1.8 million during the six months ended June 30, 2022 to $13.9 million, compared to $12.1 million for the six months ended June 30, 2021. The increase was primarily due to:

Interest income for the six months ended June 30, 2022 and 2021 was $0.2 million and $20 thousand, respectively. The increase in interest income was due to the increase in average interest rates during the respective periods.

Other income (expense), net for the six months ended June 30, 2022 was $0.1 million. The other income of $0.1 million for the six months ended June 30, 2022 was primarily related to a grant received from a Massachusetts economic development and investment agency. Other income (expense), net for the six months ended June 30, 2021 was insignificant.

Since our inception, we have incurred significant operating losses. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for the next several years, if at all. Through ~~March 31,~~June 30, 2022, we have funded our operations primarily with payments received in connection with collaboration agreements, proceeds from equity and debt financing, most recently, with proceeds from our IPO, Follow-On Offering and ~~Follow-On Offering. In February 2021,~~our at-the market offering facility with Jefferies LLC ("ATM Facility"). During the three and six months ended June 30, 2022, we ~~completed~~raised $3.1 million, under the ~~Follow-on Offering~~ATM Facility, pursuant to which we ~~received aggregate net proceeds~~sold 958,663 shares of ~~approximately $56.4 million from the sale of~~our common stock. See Note 1 to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for further information on the ATM Facility. As of ~~March 31,~~June 30, 2022, we had cash and cash equivalents of ~~$122.9~~$105.6 million.

The following table summarizes our sources and uses of cash for each of the periods presented:


	THREE MONTHS ENDED MARCH 31,						SIX MONTHS ENDED JUNE 30,
	2022			2021			2022			2021
	(in thousands)						(in thousands)
Net cash used in operating activities	$	(20,434	)	$	(20,584	)	$	(40,910	)	$	(40,225	)
Net cash used in investing activities		(194	)		(247	)		(274	)		(521	)
Net cash provided by financing activities		29			55,403			3,232			55,456
Net (decrease) increase in cash, cash equivalents and restricted cash	$	(20,599	)	$	34,572		$	(37,952	)	$	14,710

During the ~~three~~six months ended ~~March 31,~~June 30, 2022, operating activities used ~~$20.4~~$40.9 million of cash, primarily resulting from our net loss of ~~$21.0~~$43.3 million and changes in our operating assets and liabilities of ~~$4.1~~$7.4 million, partially offset by net non-cash charges of ~~$4.7~~$9.7 million. Net cash used by changes in our operating assets and liabilities for the ~~three~~six months ended ~~March 31,~~June 30, 2022 consisted primarily of a ~~$2.9~~$5.9 million decrease in deferred revenue, a ~~$2.4~~$4.8 million decrease in operating lease liabilities, a ~~$0.9~~$0.4 million increase in prepaid expenses and other current assets, a ~~$1.7~~$2.9 million increase in accrued expenses, all of which were partially offset by a $3.0 million decrease in accounts receivable. The decrease in deferred revenue during the ~~three~~six months ended ~~March 31,~~June 30, 2022 was due to the revenue we recognized in that same period under the 2018 Roche Agreement.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, operating activities used ~~$20.6~~$40.2 million of cash, primarily resulting from our net loss of ~~$15.4~~$34.5 million and changes in our operating assets and liabilities of ~~$9.6~~$14.7 million, partially offset by net non-cash charges of ~~$4.4~~$8.9 million. Net cash used by changes in our operating assets and liabilities for the ~~three~~six months ended ~~March 31,~~June 30, 2021 consisted primarily of a ~~$5.5~~$9.8 million decrease in deferred revenue, a ~~$2.3~~$4.6 million decrease in operating lease liabilities, a ~~$2.6~~$2.0 million decrease in accrued expenses and a ~~$1.6~~$0.4 million increase in prepaid expenses and other current assets, all of which were partially offset by a $1.9 million decrease in accounts receivable. The decrease in deferred revenue during the ~~three~~six months ended ~~March 31,~~June 30, 2021 was due to the revenue we recognized in that same period under the 2018 Roche Agreement.

In all periods presented, other changes in prepaid expenses and other current assets, accounts receivable, accounts payable, accrued expenses and other liabilities not described above were generally due to growth in our business, the advancement of our research programs and the timing of vendor invoicing and payments. In all periods presented, decreases in operating lease liabilities were primarily due to our recurring payments made under recorded operating lease liabilities, including those arising from embedded leases.

During the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, net cash used in investing activities ~~for each period~~ was ~~$0.2~~$0.3 million and $0.5 million, respectively, consisting of purchases of property and equipment.

The purchases of property and equipment in each period were primarily for equipment purchases and leasehold improvements related to the expansion of our research and development activities and the growth of our business.

During the ~~three~~six months ended ~~March 31,~~June 30, 2022, net cash provided by financing activities was ~~$29 thousand~~$3.2 million consisting of proceeds from the ATM Facility, employee stock purchase plan issuances, and stock option exercises during the period.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, net cash provided by financing activities was ~~$55.4~~$55.5 million, consisting of net proceeds from the Follow-on Offering in February 2021, of $56.4 million, in addition to proceeds of ~~$0.3~~$1.0 million from stock option exercises during the ~~quarter,~~period, offset by the payment of ~~$1.3~~$1.9 million of IPO and Follow-on Offering costs.

We expect that our expenses will increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development. The timing and amount of our operating and capital expenditures will depend largely on:

We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the ~~second half~~fourth quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders' interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates,

or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, including due to adverse macroeconomic conditions such as rising interest rates, we would be required to delay, scale back or discontinue our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

There have been no material changes to our contractual obligations from those described in our 2021 Form 10-K. For additional information, see Note 8 and 9 to our condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, revenue, costs and expenses, and related disclosures. Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” in our 2021 Form 10-K. If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying these policies, our reported financial condition and results of operations could be materially affected. There have been no significant changes to our critical accounting policies from those described in the 2021 Form 10-K.

A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.

As of ~~March 31,~~June 30, 2022, we had cash and cash equivalents of ~~$122.9~~$105.6 million, which consisted of cash and money market funds. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these balances, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents.

We are not currently exposed to significant market risk related to changes in interest rates or foreign currency exchange rates. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.

We do not believe that inflation has had a material effect on our business, financial condition, or results of operations. Our operations may be subject to inflation in the future.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934). Based on that evaluation, our Principal Executive Officer and Principal

Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of ~~March 31,~~June 30, 2022.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended ~~March 31,~~June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Investing in our common stock involves a high degree of risk. In addition to the other information in this Quarterly Report on Form 10-Q, including our interim condensed consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Results of Operations and Financial Condition”, you should carefully consider the factors described in the section titled “Risk Factors” in our 2021 Form 10-K. There have been no material changes to our risk factors as previously disclosed in our 2021 Form 10-K.

On October 29, 2020, the SEC declared effective our registration statement on Form S-1 (File No. 333-249422), as amended, filed in connection with our IPO, or the Registration Statement. Pursuant to the Registration Statement, we registered the offer and sale of 5,073,529 shares of our common stock with a proposed maximum aggregate offering price of approximately $91.3 million. On November 3, 2020, we issued and sold 4,411,765 shares of our common stock at a price to the public of $16.00 per share. Upon completion of the IPO on November 3, 2020, we received net proceeds of approximately $65.6 million, after deducting underwriting discounts and commissions, but before deducting offering costs payable by us, which were $2.6 million. On November 12, 2020, in connection with the full exercise of the over-allotment option granted to the underwriters of our IPO, we issued and sold 661,764 additional shares of common stock at a price of $16.00 per share, generating additional net proceeds of $9.8 million after deducting underwriting discounts of $0.7 million.

~~The~~As of June 30, 2022, we estimate that we have used 100% of the net proceeds for advancing the clinical development of ~~approximately $72.5 million have been invested in money market funds.~~our product candidates, development of additional product candidates as well as for working capital and general corporate purposes. There ~~has been~~were no material ~~change~~changes in the ~~expected~~ use of the net proceeds from our IPO as described in our final prospectus relating to the Registration Statement, filed with the SEC on October 30, 2020 pursuant to Rule 424(b)(4).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Delaware		46-2431115
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

200 Arsenal Yards Blvd, Suite 210 Watertown, MA		02472
(Address of principal executive offices)		(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	SQZ	New York Stock Exchange


		Page
	Forward-Looking Statements		1
PART I.	FINANCIAL INFORMATION		2
Item 1.	Financial Statements (Unaudited):
	Condensed Consolidated Balance Sheets		2
	Condensed Consolidated Statements of Operations and Comprehensive Loss		3
	Condensed Consolidated Statements of Stockholders’ Equity		4
	Condensed Consolidated Statements of Cash Flows		5
	Notes to Unaudited Condensed Consolidated Financial Statements		6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		1415
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		2327
Item 4.	Controls and Procedures		2327
PART II.	OTHER INFORMATION		2528
Item 1.	Legal Proceedings		2528
Item 1A.	Risk Factors		2528
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		2629
Item 3.	Defaults Upon Senior Securities		2629
Item 4.	Mine Safety Disclosures		2629
Item 5.	Other Information		2629
Item 6.	Exhibits		2729
Signatures			2832


	FOR THE SIX MONTHS ENDED JUNE 30,
	2022		2021		CHANGE
	(in thousands)
Direct research and development expenses by program:
SQZ-PBMC-HPV	$	4,218	$	7,127	$	(2,909	)
SQZ-AAC-HPV		2,887		2,110		777
SQZ-eAPC-HPV		6,055		5,214		841
Other programs		6,345		4,501		1,844
Unallocated research and development expenses:
Personnel related (including stock-based compensation)		11,268		8,674		2,594
Facility related		2,721		2,565		156
Laboratory and consumable materials		646		596		50
Platform-related external services and other		1,631		1,635		(4	)
Total research and development expenses	$	35,771	$	32,422	$	3,349


	SQZ Biotechnologies Company

Date: ~~May 10,~~August 4, 2022	By:	/s/ Armon Sharei, Ph.D.
		Armon Sharei, Ph.D.
		President and Chief Executive Officer
		(principal executive officer)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒


		Emerging growth company	☒



Date: August 4, 2022	By:	/s/ Micah Zajic
		Micah Zajic
		Chief Financial Officer
		(principal financial officer)